Outcomes with first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs physician's choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER22-advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.

Abstract

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, JUN 02-06, 2023